OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VALN
Valneva SE
There isn't enough reported data to score VALN yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VALN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Weak |
VALN's revenue, profitability, cash flow and balance sheet are all currently under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
VALN PE Valuation
VALN has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over VALN on the outlook, with more favorable earnings and revenue expectations.
VALN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect VALN's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus VALN down 1,613%.
VALN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$1.21 | -1613% |
| Q3 2025 | -$1.16 | -1155% |
| Q2 2025 | -$0.73 | -$0.43 |
| Q1 2025 | -$0.98 | -$0.83 |
| Q4 2024 | $0.08 | +$1.45 |
| Q3 2024 | $0.11 | +$1.65 |
| Q2 2024 | -$0.30 | -140% |
| Q1 2024 | -$0.15 | +$2.34 |
VALN has swung to a loss: it lost $1.21 per share over the past year, after a profit the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the stronger quarterly revenue trend. Revenue is up 72% for OSCR versus down 9.9% for VALN.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
VALN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $53M | -9.9% |
| Q3 2025 | $32.7M | -36% |
| Q2 2025 | $53.7M | +27% |
| Q1 2025 | $54.7M | +50% |
| Q4 2024 | $58.8M | +26% |
| Q3 2024 | $50.9M | +20% |
| Q2 2024 | $42.3M | -5.4% |
| Q1 2024 | $36.4M | -2.3% |
VALN's revenue fell from its 2021 peak and has held roughly level since: $53M last quarter, down 9.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -59% | -20 points |
| Q3 2025 | -126% | -99 points |
| Q2 2025 | -22% | +34 points |
| Q1 2025 | -12% | -220 points |
| Q4 2024 | -39% | +20 points |
| Q3 2024 | -27% | +31 points |
| Q2 2024 | -57% | -11 points |
| Q1 2024 | 208% | +258 points |
VALN's operating margin was −59% last quarter, down 20 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with VALN at up 31%.
VALN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$28.4M | -552% |
| Q3 2025 | -$20.1M | +$9.2M |
| Q2 2025 | -$4.5M | +$37.1M |
| Q1 2025 | -$10.7M | +$25.9M |
| Q4 2024 | $6.3M | +$86M |
| Q3 2024 | -$29.3M | +$51.4M |
| Q2 2024 | -$41.6M | +$7.8M |
| Q1 2024 | -$36.6M | -$5.4M |
VALN has burned cash in most quarters: −$64M over the past year, against −$101M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VALN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +96% | +82.3M shares |
| 1 year | +15% | +22.5M shares |
| 3 years | +46% | +52.7M shares |
| 5 years | +266% | +122M shares |
| Available history | +307% | +127M shares |
VALN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q3 2023 | $49,991 |
| Q2 2023 | $101,092 |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
VALN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | 5.5x | High |
| Q4 2019 | 2.3x | Moderate |
| Q3 2019 | 1.3x | Healthy |
| Q2 2019 | 0.4x | Very low |
| Q1 2019 | 0.5x | Very low |
| Q4 2018 | -1.4x | Net Cash |
| Q3 2018 | 18.4x | High |
| Q2 2018 | 12.1x | High |
VALN's net debt is about 5.5 years of its operating earnings (EBITDA), up from less than a year a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VALN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.9 | Neutral |
| Stochastic | 23.6 | Neutral |
VALN's weekly RSI is 46 (neutral) and its Stochastic is 24 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VALN PE vs Healthcare Sector
VALN has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over VALN on trend strength, trading above more of its moving averages.
VALN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.66 | 1.8% above |
| 20 week MA | $5.81 | 0.9% below |
| 50 week MA | $7.03 | 18% below |
| 100 week MA | $7.19 | 20% below |
| 200 week MA | $8.51 | 32% below |
VALN has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 32% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VALN on returns for 2026, with the stronger performance.
VALN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $29.5 | $57.3 | +94% |
| 2022 | $57.3 | $14.2 | -75% |
| 2023 | $14.2 | $10.4 | -27% |
| 2024 | $10.4 | $4.33 | -58% |
| 2025 | $4.33 | $8.41 | +94% |
| 2026 YTD | $8.41 | $5.76 | -32% |
VALN has finished lower in three of the last five years. It's down 32% so far in 2026.